Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease

Annals of Clinical Psychiatry

Volumn 20, Issue 1, 2008, Pages 1-3

  Duff, Kevin ^a   Beglinger, Leigh J ^a   O'Rourke, Margaret E ^a   Nopoulos, Peg ^a   Paulson, Henry L ^a,b   Paulsen, Jane S ^c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Cognition; Huntington's disease; Motor; Psychiatric symptoms; Risperidone; Treatment

Indexed keywords

RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; MOTOR DYSFUNCTION; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ACTIVITIES OF DAILY LIVING; ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MENTAL DISORDERS; MIDDLE AGED; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES; RISPERIDONE;

EID: 39749165003     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230701844802     Document Type: Article

References (14)

1. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366-372.
2. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology. 2003;61:1551-1556.
3. Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 2005;65(2):286-292.
4. van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry. 1997;63(1):35-39.
5. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB, Jr., Siemers E, Shoulson I. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology. 2000;54(2):452-458.
6. Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Lyons B, Grossman F. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64(2):134-143.
7. De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg. 2005;107(6):497-508.
8. Parsa MA, Szigethy E, Voci JM, Meltzer HY. Risperidone in treatment of choreoathetosis of Huntington's disease. J Clin Psychopharmacol. 1997;17(2):134-135.
9. Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington's disease. Eur J Neurol. 2002;9(2):182-183.
10. Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington's disease. Am J Geriatr Psychiatry. 1998;6(4):347-349.
11. Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol. 1999;19(1):101-103.
12. Shoulson I, Kurlan R, Rubin A. Assessment of functional capacity in neurodegenerative disorders: Huntington's disease as a prototype, In: Munsat TL. Quantification of Neurologic Deficits. Boston, Butterworth; 1989;285-309.
13. Beglinger LJ, Langbehn DR, Duff K, Stierman L, Black DW, Nehl C, Anderson K, Penziner E, Paulsen JS. Probability of Obsessive and Compulsive symptoms in Huntington's Disease. Biol Psychiatry. 2007;61:415-418.
14. Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, Bossie CA, Davidson M, Burtea V, Zhu Y, Trivedi JK. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res. 2006;85(1-3):254-265.